Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lirimilast is an effective, selective, and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 49 nM). Lirimilast has potently anti-inflammatory properties. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Lirimilast is an effective, selective, and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 49 nM). Lirimilast has potently anti-inflammatory properties. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease. |
Targets&IC50 | PDE4:42 nM |
In vitro | Lirimilast is reported to be 5-fold more effective than Cilomilast and equipotent with CDP-840, In PDE4 assays, using freshly prepared PDE4 from human PMNL[1]. |
In vivo | When compared in a rat model of lung neutrophilic inflammation, Lirimilast is found to be 3-fold more potent than Cilomilast. Since Lirimilast is orally active in the guinea-pig at 3 mg/kg and in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio [2]. |
Synonyms | BAY 19-8004 |
Molecular Weight | 443.26 |
Formula | C17H12Cl2N2O6S |
CAS No. | 329306-27-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lirimilast 329306-27-6 Metabolism PDE BAY 19-8004 inhibitor inhibit